Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 3, 2004, Pages 323-333

  Imbert Bismut, Françoise ^a,b   Messous, Djamila ^a   Thibaut, Vincent ^a   Myers, Rob B ^a   Piton, Annie ^a   Thabut, Dominique ^a   Devers, Laure ^a   Hainque, Bernard ^a   Mercadier, Anne ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Assay standardization; Enzyme calibration; Liver fibrosis markers; Reference ranges; Result transferability; Test combinations

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ACCURACY; ADULT; ANALYTIC METHOD; ANALYZER; ARTICLE; BLOOD DONOR; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FIBROSIS; HEPATITIS C; HOSPITAL PATIENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE; RELIABILITY; REPRODUCIBILITY; STORAGE TEMPERATURE; VALIDATION PROCESS;

AGE FACTORS; ALANINE TRANSAMINASE; ALPHA-MACROGLOBULINS; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; BILIRUBIN; BIOLOGICAL MARKERS; BLOOD DONORS; BODY MASS INDEX; CLINICAL CHEMISTRY TESTS; CONFIDENCE INTERVALS; DIAGNOSTIC TESTS, ROUTINE; ENZYME STABILITY; FIBROSIS; FREEZING; GAMMA-GLUTAMYLTRANSFERASE; HAPTOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SEX FACTORS; TEMPERATURE;

EID: 11144355931     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.058     Document Type: Article

References (64)

1. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396-400.
2. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:543-8.
3. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the liver (AFEF), Hepatology 2000;32:477-81.
4. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous biopsy of the liver. Lancet 1986;8480:523-5.
5. Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep 2001;3:12-8.
6. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558-63.
7. Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36:Suppl.1:557-64.
8. Mastroianni CM, Liuzzi GM, D'Ettorre G, Lichtner M, Forcina G, Di Campli NF, et al. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients ci-infected with HCV and HIV. HIV Clin Trials 2002;3:310-5.
9. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002;316:71-81.
10. Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002;14:1133-41.
11. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
12. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
13. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infections: a prospective study. Lancet 2001;357:1069-75.
14. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussali J, et al. Biochemical markers of liver cirrhosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat 2002;9:128-33.
15. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2002.
16. Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al. Life is possible without biopsy in patients with chronic hepatitis C: validation of biochemical markers of liver fibrosis and activity in 1570 patients and blood donors [abstract]. AASLD Boston 2002.
17. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated interferon alfa-2b and ribavirin combination [abstract]. Hepatology 2002;36:351A.
18. Myers RP, Benhamou Y, Imbert-Bismut F, Bochet M, Thibaut V, Ratziu V, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003;17:721-5.
19. Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al. The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C: prospective validation in 534 patients [abstract]. Hepatology 2002;36:351A.
20. Kawser CA, Iredale JP, Winwood PJ, Arthur MJP. Rat hepatic stellate cell expression of α2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci 1998;95:179-86.
21. Tiggelman AM, Linthorst C, Boers W, Brand HS, Chamuleau RA. Transforming growth factor-beta-induced collagen synthesis by human liver myofibroblasts is inhibited by alpha2-macroglobulin. J Hepatol 1997;26:1220-8.
22. Bacq Y, Schillio Y, Brechot J-F, De Muret A, Dubois F, Metman E-H. Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol 1993;17:364-9.
23. Louagie HK, Brouwer JT, Delanghe JR, De Buyzere ML, Leroux-Roels GG. Haptoglobin polymorphism and chronic hepatitis C. J Hepatol 1996;25:10-4.
24. Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991;100:1397-402.
25. Giannini E, Botta F, Fasoli A, Romagnoli P, Mastracci L, Ceppa P, et al. Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. Dig Dis Sci 2001;46:524-9.
26. Edwards AM, Lucas CM, Baddams HM. Modulation of gamma-glutamyltranspeptidase in normal rat hepatocytes in culture by cell density, epidermal growth factor and agents which alter cell differentiation. Carcinogenesis 1987;8:1837-42.
27. Paradis V, Laurent A, Mathurin P, Poynard T, Vidaud D, Bedossa P. Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-1 by hepatocytes. Cell Mol Biol 1996;42:525-34.
28. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
29. Craxi A, Almasio P. Diagnostic approach to liver enzyme elevation. J Hepatol 1996;25:45-51.
30. Schumann G, Bonora R, Ceriotti F, Ferard G, Ferrero CA, Franck PFH, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase [L-alanine:2-oxoglutarate aminotransferase (ALT), EC 2.6.1.2]. Clin Chem Lab Med 2002;40:718-24.
31. Szasz G, Persijn JP, van der Slik WA. A new method for the determination of γ-glutamyl-transferase. J Clin Chem Clin Biochem 1976;14:421-7.
32. Wahefeld AW, Herz G, Bernt E. Modification of the Malloy-Evelyn method for a simple, reliable determination of total bilirubin in serum [abstract]. Scand J Clin Lab Invest 1972;29 [abstract 11-12].
33. Doumas BT, Perry BN, Sasse EA, Straumfjord JV Jr. Standardization in bilirubin assays: evaluation of selected methods and stability of bilirubin solutions. Clin Chem 1973;19:984-93.
34. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al. Consensus of a group of professional societies and diagnostic companies for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 1996;34:517-20.
35. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry Standardization Project for Measurement of Apolipoproteins A1 and B. II Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-62.
36. Vassault A, Grafmeyer, D, Naudin C, Dumont G, Bailly M, Henny J, et al. Commission "For Validation of Methods" of the Societé Française de Biologie Clinique. Protocol for the validation of methods (document B, stage 3). Ann Biol Clin 1986;44:696-747.
37. Vassault A, Baud M, Castagnier M, Dumont G, Ingrand J, Mercier M, et al. Comission Validation de Techniques de la SFBC et groupe de travail SFBC/Corata "Comparaison de Techniques". Recommandations pour la comparaison de techniques. Ann Biol Clin 1992;50:727-30.
38. Vassault A, Grafmeyer D, de Graeve J, Cohen R, Beaudonnet A, Bienvenu J. Analyses de biologie médicale: spécifications et normes d'acceptabilité à l'usage de la validation de techniques. Ann Biol Clin 1999;57:685-95.
39. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS guideline EP5-A, Wayne, PA:NCCLS, February 1999.
40. Malloy HT, Evelyn KA. The determination of bilirubin with photoelectric colorimeter. J Biol Chem 1937;19:984-93.
41. Jendrassik Grof. Vereinfachte Photometrische Methoden zur Bestimmung des Blutbilirubins. Biochem Z 1938;297:81-9.
42. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341:427-34.
43. Linnet K. Evaluation of regression procedures for methods comparison studies based on regression analysis. Clin Chem 1993;39:424-32.
44. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurement from two different analytical methods. J Clin Chem Clin Biochem 1983;21:709-20.
45. Landis RJ, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-64.
46. Rossi E, Adam L, Prins A, Bulsara M, De Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-4.
47. Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di-Martino V, Thabut D, et al. Fibrotest even better than liver biopsy? [electronic letter] Clin Chem 2003. http://www.clinchem.org/cgi/eletters/49/3/450. Response (March 21, 2003).
48. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and Activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002;1:3.
49. Williams KM, Williams AE, Kline LM, Dodd RY. Stability of serum alanine aminotransferase activity. Transfusion 1987;27:431-3.
50. Donawa ME. The IVD directive: planning for compliance. Med Device Technol 2002;13:22-4.
51. Spencer S. Performance evaluation and the IVD Directive. Med Device Technol 2002;13:41-3.
52. Ferard G, Edwards J, Kanno T, Lessinger J-M, Moss DW, Schiele F, et al. Interassay calibration as a major contribution to the comparability of results in clinical enzymology. Clin Biochem 1998;31:489-94.
53. Ferard G, Lessinger JM. Preparation of enzyme calibration materials. Clin Chim Acta 1998;278:151-62.
54. Lessinger J-M, Schiele F, Vialle A, Férard G, Myara A, Guéchot J, et al. Le calibrage en enzymologie clinique: principe, conditions d'application et résultats. Ann Biol Clin 2002;60:281-6.
55. Baudner S, Bienvenu J, Blirup-Jensen S, Carlström A, Johnson AM, Milford Ward, et al. The certification of a matrix reference material for immunochemical measurement of 14 human serum proteins. CRM 470; Brussels: Community Bureau of Reference, Commission of European Communities. BCR information, Reference Materials; 1993 report EUR 15234 EN (ISSN 10 185593):1-172.
56. Whicher JT, Ritchie R, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994;40:934-8.
57. Johnson AM, Whicher JT. Effect of Certified Reference Material 470 (CRM 470) on national quality assurance programs for serum proteins in Europe. Clin Chem Lab Med 2001;39:1123-8.
58. Bienvenu J, Doche C, Later R, Manceaux JC, Pontet F, Pressac M, et al. Improvements from the reference material CRM 470 in the standardization of the determination of serum proteins. Ann Biol Clin 1997;55:37-40.
59. Blirup-Jensen S. Protein standardization III: method optimization basic principles for quantitative determination of human serum proteins on automated instruments based on turbidimetry or nephelometry. Clin Chem Lab Med 2001;39:1098-109.
60. Ledue TB, Johnson AM. Commutability of serum protein values: persisting bias among manufacturers using values assigned from the Certified Reference Material 470 (CRM 470) in the United States. Clin Chem Lab Med 2001;39:1129-33.
61. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of Peginterferon Alfa-2b and Ribavirin. Hepatology 2003;38:481-92.
62. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC group. Hepatology 1998;27:1213-9.
63. Steinmetz J, Tarallo P, Fournier B, Caces E, Siest G. Reference limits of apolipoprotein A1 and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem 1995;33:337-42.
64. Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP. Population frequency distributions of HDL, HDL2 and HDL3 cholesterol apolipoproteins A1 and B in healthy men and women in associations with age, gender, hormonal status, and sex hormone use: the Stanford Five City Project. Prev Med 2000;31:335-45.